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AbSTrACT
Objective To assess the burden of cardiovascular 
disease (cVD) at and prior to diagnosis in people with 
early rheumatoid arthritis (ra) and subsequent cVD in 
these patients.
Methods a retrospective case–control study using a 
large english primary care database. People with ra 
(n=6591) diagnosed between 2004 and 2016 (inclusive) 
were identified using a validated algorithm, matched 
1:1 by age and gender to those without ra (n=6591) 
and followed for a median of 5.4 years. We assessed 
differences in cVD at, before and after diagnosis, and 
the impact of traditional and ra- related risk factors 
(c reactive protein, ra- related autoantibodies and 
medication use) on incident cVD (a composite of 
myocardial infarction (Mi), stroke or heart failure).
results ra cases and their matched controls were both 
of mean age 58.7 (sD 15.5) at cohort entry, and 67.5% 
were female. some cVD risk factors were more common 
at ra diagnosis including smoking and diabetes; 
however, total and low- density lipoprotein cholesterol 
were lower in patients with ra. cVD was more common 
in ra at cohort entry; stroke (3.9% vs 2.7%, p<0.001), 
heart failure (1.6% vs 1.0%, p=0.001), and non- 
significantly Mi (3.1% vs 2.8%, p=0.092). excess cVD 
developed in the 5 years preceding diagnosis. after 
adjustment for traditional and ra- related risk factors, ra 
was associated with greater risk of post- diagnosis cVD 
(hr 1.33, 95% ci 1.07 to 1.65, p=0.010).
Conclusions an excess of stroke and heart failure 
occurs before diagnosis of ra. There is excess risk for 
further cardiovascular events after diagnosis, which is not 
explained by differences in traditional cVD or ra- related 
risk factors at diagnosis.
InTrOduCTIOn
The long- term prognosis of rheumatoid arthritis 
(RA), in terms of joint damage and disability, has 
improved with the availability of conventional 
synthetic disease- modifying anti- rheumatic drugs 
(csDMARDs), biological DMARDs (bDMARDs) 
and targeted synthetic DMARDs1 2 in conjunction 
with improved monitoring and treatment adjust-
ment to actively target disease remission.3 Despite 
these improvements in outcome, and possibly as 
a result of improved survival and greater detec-
tion, comorbidities are highly prevalent among 
patients with RA and are associated with prema-
ture mortality.4–8 Cardiovascular disease (CVD) 
is responsible for over 50% of premature deaths 
in RA9 with the risk of CVD in RA only partly 
explained by traditional CVD risk factors.10 Inflam-
mation has been recognised as a central process in 
the development of CVD,11 and the excess inflam-
mation present in RA has been hypothesised to be 
a determinant of the observed higher risk in RA 
either directly or through its impact on other CVD 
risk factors.12
The European League Against Rheumatism 
recommends annual CVD risk assessment for 
people with RA.13 These guidelines suggest using 
a multiplication factor of 1.5 to calculate future 
cardiovascular risk when using a whole population 
derived cardiovascular risk calculator (eg, SCORE). 
Other cardiovascular risk assessment tools, such as 
the QRESEARCH Cardiovascular Risk Algorithm 
(QRisk) 2, has RA incorporated as a variable into the 
instrument (using a multiplication factor of 1.4).14 
However, analyses using the RABBIT registry found 
a significantly greater all- cause mortality only in 
those with high disease activity.15 Long duration 
of disease may confer excess risk; however, athero-
sclerotic burden may precede the onset of clini-
cally manifest RA, in parallel with inflammation.16 
It therefore remains unclear whether all patients 
with RA are at higher CVD risk and if CVD risk 
has diverged from that of people without RA by the 
time of diagnosis.
The primary objective of this study was to 
describe the prevalence of established CVD and 
risk factors at diagnosis in a contemporary RA 
population in England compared with age- matched 
and gender- matched controls. Secondary objectives 
were: (1) to explore the timeframe in which any 
excess events accumulate prior to diagnosis of RA 
when compared with controls, (2) whether RA is 
associated with a greater risk of CVD events within 
the first few years after diagnosis compared with 
controls, (3) to explore the association between 
traditional CVD risk factors, RA- related factors and 
cardiovascular outcomes comparing across RA cases 
and controls and (4) examine whether these factors 
account for any excess CVD risk in people with RA. 
We hypothesised that there would be a higher inci-
dence of CVD in people with RA at, prior to and 
following diagnosis.
MeThOdS
data sources and cohort
The Royal College of General Practitioners (RCGP) 
Research and Surveillance Centre (RSC) database 
was used for this study. It comprises pseudonymised 
primary care records for individuals registered with 
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a large network of General Practice (GP) practices, providing 
a broadly representative sample of the English primary care 
population.17 Data were available from 164 GP practices across 
England with a registered population of 1 475 762 people. The 
dataset contains information on clinical diagnoses, anthropo-
metric measurements (eg, body mass index (BMI)), laboratory 
tests (eg, C reactive protein (CRP)) and prescriptions, coded 
with the Read coding system (a thesaurus of clinical terms). UK 
general practice lends itself to this type of study because it is 
a registration- based system (each patient registers with a single 
GP); it has been computerised since the 1990s, with electronic 
laboratory links, and pay- for- performance data available from 
2004 that has resulted in consistent high- quality clinical data 
entry about chronic disease.
We included adults with a diagnosis of RA between 1 January 
2004 and 1 January 2017. RA was defined using criteria that 
have been validated in a similar UK database, the Clinical Prac-
tice Research Datalink.18 In brief, RA was considered to be 
confirmed by either two disease codes consistent with a diag-
nosis of RA (online supplementary appendix 1) and no alterna-
tive diagnosis (psoriatic arthritis, ankylosing spondylitis or other 
spondyloarthropathy) or one disease code and a prescription for 
a DMARD with no alternative indication recorded. Once RA 
was identified, the index date was the date of diagnosis of RA 
indicated by first diagnostic code in the clinical record. Patients 
were required to have a minimum of 3 months between registra-
tion with their current GP and RA diagnosis to be considered a 
true incident case (online supplementary appendix 2).
Patients with RA were age and gender- matched (using a 1:1 
ratio; online supplementary appendix 2) at GP practice level 
with individuals without RA. The index date for controls was 
defined as the RA diagnosis date of their matched counterpart.
Primary objective
Our primary objective was to compare the prevalence of CVD 
and CVD risk factors at diagnosis between the cases and controls. 
CVD comprised an a priori composite of myocardial infarction 
(MI), stroke and heart failure.
Risk factors were selected for inclusion based on clinical exper-
tise and existing literature demonstrating an established associ-
ation with CVD (traditional risk factors) or evidence to support 
an association with CVD among individuals with RA (RA- related 
factors).9 19–22 We explored ethnicity, smoking status, BMI, 
cholesterol, blood pressure and comorbidities (chronic kidney 
disease [CKD] stages III–V, diabetes [with breakdown by diabetes 
type] and atrial fibrillation). Numerical data including choles-
terol, CRP and blood pressure values were derived by taking the 
mean of the three most recent values in the 12 months before the 
index date. Where three values were unavailable, the mean of 
two or a single available value were used. For those missing data, 
multiple imputation was used as outlined below. Values recorded 
more than 12 months before the index date were not consid-
ered except for BMI where the most recently recorded value was 
used. RA seropositivity was defined as seropositivity for either 
anti- cyclic citrullinated peptide antibodies or rheumatoid factor 
where recorded. The presence of medical conditions prior to 
diagnosis was determined by the presence of indicative Read 
diagnosis codes in the electronic health record at any time prior 
to diagnosis. This includes conditions that had been diagnosed 
at the patients’ previous GP practice (if relevant) and transferred 
with their record.
We also report the use of prescribed non- steroidal anti- 
inflammatory drugs (NSAIDs), glucocorticoids and DMARDs 
at the time the diagnosis was first recorded in primary care. 
This was defined as the presence of an issued prescription in the 
3 months preceding or on the date of the first diagnostic code 
for RA. For comparison, we also report the proportion of people 
with NSAID, glucocorticoid and DMARD prescriptions at any 
point during the 3 years post- diagnosis. Anti- platelet agents were 
defined as aspirin or ADP receptor inhibitors, and lipid- lowering 
therapy was defined as statins, fibrates or ezetimibe.
Secondary objectives
For our secondary objectives, we compared: (1) the incidence 
of CVD in cases and controls before RA diagnosis, within 5 
years, 5–10 years or more than 10 years, (2) time to the CVD 
composite, and each component endpoint, in cases and controls 
after the diagnosis date, (3) the associations between traditional 
and possible RA- specific CVD risk factors (see below) on the 
CVD composite after diagnosis and (4) whether these CVD 
risk factors explain any differences between CVD risk in those 
with and without RA. For secondary objectives 2–4, we used a 
matched cohort design, using the same cases and controls as in 
the earlier study components. Data on cause- specific mortality 
were not available; therefore, cardiovascular mortality was not 
included in the composite endpoint.
Statistical analyses
We evaluated differences in baseline characteristics between 
those with and without RA using McNemar's or McNemar- 
Bowker tests for categorical variables and the paired t- test for 
continuous data. In the matched cohort components of the study, 
event rates were calculated as the number of events divided by 
the total person- years of follow- up (expressed per 1000 person- 
years). The follow- up period started at RA diagnosis (or date of 
case diagnosis for matched controls) and extended to the first 
of: 1 January 2017, loss to follow- up or death. Adjusted HRs 
and 95% CIs were estimated using Cox regression. Cumulative 
incidence curves were used to compare the unadjusted incidence 
of the composite and component outcomes in patients with and 
without RA.
The influence of traditional cardiovascular risk factors (age, 
sex, ethnicity, systolic blood pressure, low- density lipopro-
tein [LDL] cholesterol, diabetes and CKD stage III–V) and 
RA- specific factors (glucocorticoid use, disease- modifying anti- 
rheumatic drug [DMARD] use, seropositivity and CRP) on 
the composite CVD outcome was compared between RA and 
non- RA groups using separate models for the case and control 
cohorts. To explore possible heterogeneity in CVD risk factors 
between cases and controls post hoc, we generated a combined 
model with cases and controls and additional interaction terms 
between RA status and risk factors associated with CVD in either 
of the separate models. Two sensitivity analyses were performed 
for the separate models: First, by including existing CVD at 
baseline as binary variables to determine any impact on other 
risk factors. Second by using an extended composite endpoint of 
MI, stroke, heart failure, coronary artery disease, percutaneous 
coronary intervention and angina.
To explore whether differences in traditional CVD risk 
factors or RA- specific CVD risk factors explain any of the excess 
cardiovascular risk in people with RA a model with cases and 
controls (combined) was performed. This was done by calcu-
lating the association between RA and CVD both before and 
after adjustment for the traditional and RA- specific CVD risk 
factors described above, with stratification by matched set. 
For models that included incomplete data, we used multiple 
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Table 1 Baseline characteristics among patients with RA at 
diagnosis and age- matched and sex- matched controls
rA (n=6591) no rA (n=6591) P value
baseline characteristics
Age (years) 58.67 (15.54) 58.67 (15.54) NA
Male sex 2142 (32.5) 2142 (32.5) NA
Ethnicity* <0.001
  White 4883 (91.6) 4418 (94.6)
  Asian 255 (4.8) 147 (3.1)
  Black 128 (2.4) 69 (1.5)
  Mixed 26 (0.5) 18 (0.4)
  Other 36 (0.7) 18 (0.4)
Smoking status* <0.001
  Never smoked 1853 (30.0) 2247 (35.8)
  Active smoker 1348 (21.9) 1187 (18.9)
  Ex- smoker 2968 (48.1) 2838 (45.2)
Clinical measurements
BMI (kg/m2)* 27.67 (5.97) 27.23 (5.56) <0.001
Systolic BP, mm Hg* 130.86 (16.19) 131.10 (15.95) 0.084
Diastolic BP, mm Hg* 76.82 (9.68) 77.31 (9.46) 0.003
Total cholesterol (mmol/L)* 5.07 (1.13) 5.20 (1.12) <0.001
LDL cholesterol (mmol/L)* 2.96 (1.00) 3.05 (1.01) 0.005
HDL cholesterol (mmol/L)* 1.47 (0.45) 1.50 (0.44) <0.001
Positive RF or anti- CCP 
antibodies*
1885 (28.1) 159 (2.4) <0.001
CRP (mg/L)* 20.0 (32.7) 7.4 (16.8) <0.001
Comorbidities
Chronic kidney disease (stage 
III–V)
618 (9.4) 614 (9.3) 0.923
Diabetes (any) 735 (11.2) 635 (9.6) 0.004
  Type 1 44 (0.7) 26 (0.4) 0.025
  Type 2 691 (10.5) 609 (9.2) <0.001
Atrial fibrillation 237 (3.6) 185 (2.8) 0.009
Myocardial infarction 202 (3.1) 169 (2.6) 0.079
Stroke 254 (3.9) 180 (2.7) <0.001
Heart failure 108 (1.6) 65 (1.0) 0.001
Medication use†
ACE inhibitor 1415 (21.5) 1359 (20.6) 0.203
Angiotensin receptor blocker 536 (8.1) 528 (8.0) 0.816
Calcium channel blocker 1297 (19.7) 1184 (18.0) 0.007
Beta- blocker 1260 (19.1) 1294 (19.6) 0.452
Anti- platelet agents 1374 (20.8) 1371 (20.8) 0.962
Lipid lowering medication 1811 (27.5) 1731 (26.3) 0.078
NSAID 1962 (29.8) 430 (6.5) <0.001
Glucocorticoids 2001 (30.4) 899 (13.6) <0.001
Methotrexate 992 (15.1) 8 (0.1) <0.001
csDMARD 1263 (19.2) 90 (1.4) <0.001
bDMARD 19 (0.3) 0 (0.0) <0.001
Data are mean (SD) or n (%). P values from χ2 test or t- test are provided.
*The following variables had missing values (n): ethnicity in RA: n=1263; no RA: n=1921; smoking 
status in RA: n=422; no RA: n=319; BMI in RA: n=520; no RA: n=701; blood pressure in RA: n=191; 
no RA: n=221; cholesterol in RA: n=1678; no RA: n=2162; CRP in RA: n=2172; no RA: n=4499; one or 
more RA antibodies were measured in RA: n=3550, no RA: n=992.
†Any prescription on or within 3 months prior to the first diagnosis code in primary care.
anti- CCP, anti- cyclic citrullinated peptide ; bDMARD, biological disease- modifying anti- rheumatic drug; 
BMI, body mass index; BP, blood pressure; CRP, C reactive protein; csDMARD, conventional synthetic 
disease- modifying anti- rheumatic drug; HDL, high- density lipoprotein; LDL, low- density lipoprotein; 
NSAID, non- steroidal anti- inflammatory; RA, rheumatoid arthritis.
imputation with five iterations to generate missing values. HRs 
presented are those from pooled models. All statistical analyses 
were performed in R statistical package software version 3.2.1. 
Multiple imputation was performed using the MICE package.
Patient and public involvement
There was no direct patient involvement in study design, anal-
ysis, interpretation or writing.
ethical considerations
The study did not require formal research ethics committee as it 
used anonymised routinely collected healthcare data. This was 
based on the outputs from the National Health Service (NHS) 
Health Research Authority research decision tool (http://www. 
hra- decisiontools. org. uk/ research/) and the University of Surrey 
owned Self- Assessment for Governance and Ethics tool. No 
patient identifiable information was available to researchers. 
All participating practices display information to patients 
regarding data use through the RCGP RSC network. All patients 
who choose to opt out of data sharing do not have their data 
processed. Approval for data access and use was granted by the 
RCGP RSC Research Committee.
reSulTS
The prevalence of CVd at diagnosis
Following matching, data for 13 182 individuals (6591 with RA, 
6591 without RA) were included. At diagnosis, people with RA 
were more likely to have a history of MI, stroke or heart failure 
(table 1), although for MI the difference was not significant.
Individuals with RA had higher rates of someadverse CV risk 
factors when compared with those without RA, including ahistory 
of active smoking and diabetes, but there was no difference in 
systolicblood pressure (table 1). Paradoxically, a higher likelihood 
of favourabletotal cholesterol and LDL cholesterol profiles was 
seen in people with RA (table 1). Medication use over time in the 
two groups is detailed in online supplementary appendix 3.
CVd incidence before diagnosis
A greater number of cardiovascular events occurred within the 
5 years preceding a diagnosis of RA compared with controls. 
CVD incidence within 5–10 years preceding a diagnosis and 
more than 10 years preceding a diagnosis were not significantly 
different (online supplementary appendix 4).
Incidence of CVd in early rA
In the matched cohort component, during a total follow- up dura-
tion of 71 067 person years (median 5.4 years in each group), 
728 incident CVD events were recorded (table 2). Event rates 
for the composite CVD endpoint and all individual components 
were greater among individuals with RA with the exception of 
stroke (figures 1–4).
risk factors for CVd events after diagnosis
In separate Cox proportional hazards models for individuals 
with and without RA, increasing age, male sex and prevalent 
CKD were significant risk factors for the composite CVD 
endpoint after the index date (figure 5 and online supplemen-
tary appendix 5). Among individuals with RA, current smoking, 
BMI and diabetes were also associated with a higher rate of the 
composite endpoint. Lastly, seropositivity was associated with 
greater cardiovascular events in the non- RA population in a fully 
adjusted model but not in the RA population. In the post hoc 
model, with interaction terms between RA and variables that 
were significantly associated with CVD in either of the separate 
models described above, we found no evidence of risk factor 
heterogeneity (no interaction term was significant).
Sensitivity analyses with the inclusion of pre- existing CVD 
in the regression model for the RA group made little difference 
to the associations above (online supplementary appendix 6). 
Repeating the Cox proportional hazards models for individuals 
with and without RA, using the extended composite endpoint, 
similar associations were observed except that BMI was 
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Table 2 Event rates of cardiovascular outcomes among individuals with and without RA
Outcome
rA (n=6591) no rA (n=6591)
no events
events per 1000 person- years
(95% CI) no events
events per 1000 person- years
(95% CI)
Composite endpoint 410 10.62 (9.61 to 11.69) 318 8.13 (7.26 to 9.07)
Myocardial Infarction 123 3.10 (2.57 to 3.69) 78 1.95 (1.54 to 2.43)
Stroke 170 4.29 (3.67 to 4.99) 152 3.82 (3.24 to 4.48)
Congestivecardiac failure* 158 3.98 (3.39 to 4.65) 109 2.72 (2.23 to 3.29)
*People with pre- existing heart failure were excluded from this calculation (RA: 108; no RA: 65).
RA, rheumatoid arthritis; MI, myocardial infarction.
Figure 1 Cumulative incidence of the composite endpoint (myocardial 
infarction, stroke or heart failure) in people with rheumatoid arthritis 
(RA) and matched controls without RA.
Figure 2 Cumulative incidence of myocardial infarction in people with 
rheumatoid arthritis (RA) and matched controls without RA.
significantly associated with the extended CVD endpoint in both 
groups, rather than RA only (online supplementary appendix 7).
In the overall cohort, the unadjusted HR for the association 
of RA with the composite endpoint was 1.40 (95% CI 1.19 to 
1.64, p<0.001). After adjustment for potential confounders 
including traditional and RA- related factors (online supple-
mentary appendix 8), the HR for the composite endpoint was 
not substantially attenuated (HR 1.33, 95% CI 1.07 to 1.65, 
p=0.010).
dISCuSSIOn
People with newly diagnosed RA have an excess of stroke and 
heart failure that occurs predominantly in the 5 years preceding 
their diagnosis. The profile of individuals with newly diagnosed 
RA is not typical of a high- risk cardiovascular cohort, with 
comparable levels of systolic blood pressure, with paradoxically 
lower Total Cholesterol and LDL cholesterol levels, compared 
with individuals without RA. Despite this, in the immediate 
period following diagnosis, we observed a near 1.4- fold higher 
risk of CVD.
higher CVd risk precedes diagnosis
We observed more prevalent CVD among individuals at diag-
nosis of RA, as compared with non- RA controls. A history 
of stroke and heart failure was significantly more common 
among those with RA, and a history of MI was more common, 
although not significantly. Our findings suggest a significantly 
higher event rates for CVD in the 5- year period immediately 
preceding a diagnosis. These data support previous analyses 
using the Finnish nationwide disease register, which suggests 
elevated cardiovascular risk precedes the clinical onset of RA,22 
and the Rochester Epidemiology Project, where patients were 
more likely to be hospitalised for MI than age- matched and sex- 
matched controls in the 2 years preceding a diagnosis.20 A large 
Swedish population- based study found no increased prevalence 
of MI, angina or ischaemic heart disease in early RA, but they did 
not explore stroke or heart failure.23
Subsequent CVd risk is not explained by traditional risk 
factors or rA characteristics at diagnosis
People with RA had a greater CVD risk after diagnosis than those 
without both before (HR 1.40, 95% CI 1.19 to 1.64, p<0.001) 
and after adjustment (HR 1.33, 95% CI 1.07 to 1.65, p=0.010) 
for baseline differences. This adjustment included RA- related 
factors such as inflammatory markers, seropositivity and use of 
glucocorticoids at diagnosis. Our findings are consistent with 
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Figure 3 Cumulative incidence of stroke in people with rheumatoid 
arthritis (RA) and matched controls without RA.
Figure 4 Cumulative incidence of heart failure in people with 
rheumatoid arthritis (RA) and matched controls without RA.
Figure 5 Association of cardiovascular risk factors and the composite 
endpoint among individuals with and without RA. BMI, body mass 
index; BP, blood pressure; CKD, chronic kidney disease; CRP, C reactive 
protein; csDMARD, conventional synthetic disease- modifying anti- 
rheumatic drug; LDL, low- density lipoprotein.
another cohort study within the Rochester Epidemiology Project, 
which suggested higher CVD risk in early RA in people without 
baseline CVD after adjusting for baseline CVD risk factors.24
Implications of our findings
The higher burden of CVD prior to RA diagnosis suggests that 
CVD is not just a late complication of disease. From a clinical 
standpoint, it is important to identify and risk stratify patients 
accurately. Based on the higher prevalence of CVD at diagnosis 
of RA, and the greater risk cardiovascular events thereafter, 
newly diagnosed patients should undergo thorough assessment 
for CVD and risk factors. While it is unlikely that modification of 
traditional risk factors will completely mitigate the higher CVD 
risk in people with RA, it is nevertheless important to address 
known CVD risk factors in this high- risk group. Care should be 
taken in considering CVD risk given the lipid paradox, whereby 
at a population level, those with higher LDL levels are associated 
with reduced cardiovascular events, thought to be explained by 
confounding inflammation, which follows an inverse relation-
ship with lipids.25
Strengths and limitations
Key strengths of our study include the large population- based 
sample size, RA identification using a validated algorithm and 
identification of controls from the same GP practice as cases. 
While the demographics of the RCGP RSC sample are nation-
ally representative,17 there may be some differences between 
those registered with a GP and those unregistered. The unreg-
istered population may be healthier than the registered popula-
tion, which may have diminished the differences we observed 
between RA cases and controls. The converse may also be true 
if the unregistered population includes a higher proportion of 
people with poorer health such as the homeless.
The data are observational in nature and the possibility of 
residual confounding cannot be excluded. In common with other 
studies using administrative data, our study relied on the use of 
comprehensive code lists. This limitation was mitigated against 
by using a validated approach for variable definition.26 The data 
analysed in this study were not linked to secondary care data and 
therefore relied on characteristics and outcomes from primary 
care records. Family history of CVD was not available. It is likely 
that prescription data, particularly for bDMARDs, which tend to 
be prescribed in secondary care, were not all captured in primary 
care records. Our analyses were also limited by the lack of data 
on cause- specific mortality. For the post hoc analysis of heteroge-
neity in risk factors between RA and non- RA, we may have been 
underpowered to detect small differences. Lastly, the reason for 
blood tests prior to diagnosis was not available; some investiga-
tions such as CRP will have been performed for other reasons 
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such as concurrent infection, and therefore, not all inflammation 
captured by these investigations will be attributable to RA.
COnCluSIOnS
Individuals with RA have an excess of MI, stroke and heart 
failure at diagnosis, although the differences with MI were 
not significant. This excess appears to accumulate within the 
5 years prior to diagnosis. People with RA also have an excess 
risk of cardiovascular events (predominantly MI and heart 
failure) compared with age- matched and sex- matched controls 
without RA from diagnosis onwards. The excess CVD risk is 
not explained by traditional risk factors or disease biomarkers 
present at diagnosis.
Key messages
What is already known on this subject?
 ► Cardiovascular disease (CVD) is the major cause of premature 
death in people with rheumatoid arthritis, but the timing of 
onset and causes of this excess risk remain unclear.
What might this study add?
 ► We identify that excess CVD is present at, and prior to, the 
time of diagnosis and continues in early rheumatoid arthritis. 
This excess risk is not explained by differences in traditional 
cardiovascular risk factors in people with rheumatoid arthritis 
or key rheumatoid arthritis- related factors at diagnosis (C 
reactive protein, rheumatoid arthritis- related autoantibodies 
or medication use).
how might this impact on clinical practice?
 ► Our findings underscore the importance of performing a 
thorough CVD risk assessment at diagnosis and initiating 
early management of any identified cardiovascular risk 
factors.
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